Abstract:
The present invention provides electronic systems, including device arrays, comprising functional device(s) and/or device component(s) at least partially enclosed via one or more containment chambers, such that the device(s) and/or device component(s) are at least partially, and optionally entirely, immersed in a containment fluid. Useful containment fluids for use in containment chambers of electronic devices of the invention include lubricants, electrolytes and/or electronically resistive fluids. In some embodiments, for example, electronic systems of the invention comprise one or more electronic devices and/or device components provided in free-standing and/or tethered configurations that decouple forces originating upon deformation, stretching or compression of a supporting substrate from the free standing or tethered device or device component.
Abstract:
The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Abstract:
The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Abstract:
A manufacturing execution system determines production rates of tool elements of a manufacturing system and from the production rates, the efficiency of the tool elements and the efficiency of the manufacturing process system. The manufacturing execution system is in communication with a plurality of tool elements of the manufacturing process system. The manufacturing execution system includes a process data collection device, a data retaining device such as a memory, a time recording device, and a production rate calculator. The process data collection device is in communication with sensors located on the tool elements to receive tool element status data. The data retaining device is in communication with the process data collection device to record and retain the tool element status data. The time recording device records times of changes of the tool element status data to the data retaining device. The production rate calculator receives the records of times of changes of tool element status data and from the records of times of changes determining the product fabrication rate for the manufacturing system. The production rate calculator is an apparatus that executes a method for determining the production rate of the individual tool elements, the production rate of the manufacturing process system, and the efficiency of the manufacturing process system.
Abstract:
The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Abstract:
2-pattern photonic crystal and the associated photonic devices are described here. A 2-pattern photonic crystal has a large, complete photonic band gap. It includes a TM sub-structure providing a large TM photonic band gap superimposed on a TE sub-structure providing a large TE photonic band gap. The resulting 2-pattern photonic crystals have complete photonic band gaps larger than 15%. By altering the respective sub-structures, optical devices for different polarizations (TE, TM or both) can be readily designed, and those optical devices can be integrated on the same plane.
Abstract:
2-pattern photonic crystal and the associated photonic devices are described here. A 2-pattern photonic crystal has a large, complete photonic band gap. It includes a TM sub-structure providing a large TM photonic band gap superimposed on a TE sub-structure providing a large TE photonic band gap. The resulting 2-pattern photonic crystals have complete photonic band gaps larger than 15%, By altering the respective sub-structures, optical devices for different polarizations (TE, TM or both) can be readily designed, and those optical devices can be integrated on the same plane.
Abstract:
A no-stop electronic toll collection (ETC) system based on WLAN is disclosed in the present invention. The system includes an on-board equipment, roadside equipments, a multiple access carriageway control system and a toll balance center. The communication is implemented between the on-board equipment and the roadside equipments according to the demand determined by the wireless local network protocol. The system offered in the present invention applies several technology means to effectively overcome the technology prejudice that the WLAN technology is not suitable for the ETC system. Compared with the existing technology, the present ETC system has the advantages of low cost, high efficiency, complete function and good performance index, therefore the present invention is very meaningful for the application and extension of the ETC system and the improvement of the industrial technology.
Abstract:
A no-stop electronic toll collection (ETC) system based on WLAN is disclosed in the present invention. The system includes an on-board equipment, roadside equipments, a multiple access carriageway control system and a toll balance center. The communication is implemented between the on-board equipment and the roadside equipments according to the demand determined by the wireless local network protocol. The system offered in the present invention applies several technology means to effectively overcome the technology prejudice that the WLAN technology is not suitable for the ETC system. Compared with the existing technology, the present ETC system has the advantages of low cost, high efficiency, complete function and good performance index, therefore the present invention is very meaningful for the application and extension of the ETC system and the improvement of the industrial technology.